Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of EscharEx EX-03 5% formulation compared to a placebo in the treatment of Venous Leg Ulcers VLU. This study involves adults with VLU wounds between 2 cm and 25 cm in size, with wound duration from 4 weeks to 12 months. It aims to assess how well EscharEx helps with debridement and wound bed preparation. Participants will be randomly assigned to receive either EscharEx, a sterile powder containing proteolytic enzymes enriched in bromelain, or a placebo gel without the active enzyme. The powder is mixed with sterile water to form a gel that is applied to the wound area. The study includes several periods a screening period with two visits, a daily treatment period of up to eight daily applications over two weeks, followed by weekly wound management visits for up to 12 weeks, and an optional wound closure confirmation period of up to two weeks. After wound closure, participants enter a 12-week monthly visit period to monitor wound closure durability. During the study, participants undergo clinical assessments of wound debridement and closure, including visual evaluations after each application and over the follow-up periods. Researchers will measure the incidence of complete debridement, time to wound closure, and healthy tissue development. Safety and wound healing progress are monitored throughout. The total participation can last up to 29 weeks, with regular visits to ensure detailed monitoring of wound status and treatment effects.
Actively Recruiting
Researchers are evaluating a new surgical drape with switchable adhesive technology called Comfort Release4, designed for use in negative pressure wound therapy NPWT, a treatment for chronic and acute wounds, burns, and post-operative care. This study compares the Comfort Release4 drape to the standard V.A.C. drape or other facility standard drapes in a randomized controlled trial. The goal is to reduce medical adhesive-related skin injuries MARSI, decrease pain during drape removal, and improve patient comfort while maintaining effective wound sealing. The trial has two parts Aim 1 focuses on single-use or short-term NPWT applications in 200 post-surgical patients, and Aim 2 studies serial-use NPWT applications in 100 chronic wound patients who will have about three drape changes per week. Participants will be randomly assigned to receive either the Comfort Release4 drape or the V.A.C. or standard drape. The study evaluates drape performance, pain, skin irritation, seal effectiveness, treatment compliance, and clinician acceptability. Participants will be monitored from treatment start to completion, lasting 1 to 8 weeks. Researchers will assess skin injury using the MARSI scoring system, measure pain with the Indiana Polyclinic Combined Pain Scale, record seal leaks, track medication use for pain and anxiety, and document any drop-outs from NPWT due to drape issues. Clinician feedback on drape usability will also be collected. The study runs until early 2027, aiming to support FDA clearance for this new drape technology.
Actively Recruiting
The trial investigates the treatment of nonhealing diabetic foot ulcers DFU and venous leg ulcers VLU by comparing several cellular, acellular, and matrix-like products CAMPs combined with standard of care SOC against SOC alone. It aims to determine the difference in the proportion of patients achieving complete closure of these ulcers over 12 weeks using a modified dual platform design called Matriarch. The study may evaluate up to five CAMPs per wound type, with flexibility to include more as needed. Participants receive weekly treatments either with SOC alone or SOC plus one of several CAMPs. SOC includes cleaning, debridement, moisture balance, and offloading for DFUs, or compression for VLUs. CAMPs tested include various types of amniotic membrane allografts applied weekly alongside SOC, continuing until ulcer closure or a maximum of 13 weeks. The study has multiple arms representing different CAMP products and SOC for both DFUs and VLUs. Throughout the study, participants attend weekly visits where ulcer healing progress is assessed, including measurements of closure, time to closure, and area reduction. Pain levels and quality of life improvements are monitored alongside safety through adverse event tracking up to 14 weeks. The trial involves regular assessments to evaluate the effectiveness of treatments and patient well-being during the treatment period and follow-up.
Actively Recruiting
Randomized Study of MTX-001 Injections for Non-Healing Venous Stasis Ulcers with Standard Wound Care
Researchers are evaluating the safety and effectiveness of MTX-001 in treating non-healing venous stasis ulcers VSU that have not improved after at least 4 weeks of standard wound care. This randomized, double-blind, placebo-controlled study includes patients with specific ulcer characteristics and aims to better understand MTX-001s potential benefits in wound healing compared to placebo. The study has two parts an initial lead-in phase where patients received MTX-001 weekly or every two weeks alongside standard care, followed by a randomized phase where about 70 patients receive either MTX-001 or a placebo injection weekly along with standard wound care. Treatments involve subcutaneous injections into or around the ulcer during weekly clinic visits over 12 weeks. Participants undergo safety and efficacy assessments at screening, baseline, and weeks 4, 8, and 12, including measuring wound surface area, pain levels, and overall wound healing progress. Researchers track changes in ulcer size, pain, quality of life, and total wound closure. The study also monitors tolerability and safety throughout the 12-week treatment period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of three types of placental tissue allograftsAmnionChorionAmnion, AmnionChorion, and AmnionAmnionalongside standard wound care compared to standard care alone for treating chronic non-healing diabetic foot ulcers DFUs. The study focuses on adults with chronic DFUs to understand whether adding these allografts improves healing after 12 weeks of treatment. Participants will receive one of several treatments topical application of a tri-layer dehydrated amniotic membrane allograft, a tri-layer amnionchorion allograft, a dual-layer amnionamniotic membrane allograft, or standard wound care alone. Standard care includes calcium alginate dressings, padded multi-layer dressings, offloading boots or total contact casting, debridement, and infection management. The allografts provide a protective cover and support the bodys natural healing processes and are applied directly to the ulcer without removal. During the study, participants will attend weekly visits for up to 12 weeks. Researchers will assess wound healing by measuring the percentage of ulcers healed, total time to wound closure, reduction in wound size over time, and changes in patients reported wound pain. The study includes careful monitoring of ulcer condition and overall health to evaluate treatment safety and effectiveness over the treatment period.